

## Diagnostic Role of Serum Pepsinogen Levels for Helicobacter Pylori Infection

Sayed A. M. Mahmoud\*, Maha E. Omran\*\* and Abdelhaleem A. Hassabo\*\*\*

\* Department of Medical Biochemistry, Faculty of Medicine, Al-Azhar University, Egypt

\*\* Department of Microbiology and Immunology, Faculty of Pharmacy (girls), Al-Azhar University, Egypt

\*\*\* Department of Internal Medicine, Faculty of Medicine Al-Azhar University, Egypt

### Abstract:

**Background:** Distributions of serum pepsinogen (PG) values were assessed in Helicobacter pylori-infected and non-infected Egyptian subjects. PG reflects gastric mucosal atrophy and inflammation caused by Helicobacter pylori (H. pylori) infection. Inflammation upregulates production of both PG I and PG II in gastric mucosal cells and increases the amount discharged to serum, where elevation of PG II is usually larger so that the PG I: II ratio declines. **Objectives:** evaluate PG serum levels as a reliable diagnostic marker for Helicobacter Pylori (HP) infection. **Subjects and Methods:** All individuals (100), controls (50) who were healthy and another HP infected patient group (50), were asked to provide serum samples, which were used to measure serum H. pylori antibodies using ELISA kits and PG values. The subjects, whose serum antibodies were positive, considered H. pylori infected. T-test used for comparison of two studied groups and Receiver operating characteristic (ROC) curve were used to evaluate the PGI, PGII serum levels for H. pylori infection. **Results:** Of the 100 subjects who provided blood samples, 50 were infected had serum antibody titer > 10 U/ml and 50 was considered negative <10 U/ml, the serum levels for PG I and PG II values and PG I to PG II ratio (PG I:II) were assessed, whereas in the infected subjects, these values were  $46.618 \pm 19.5031$ ,  $15.700 \pm 8.2721$  and  $3.166 \pm 0.5528$  respectively in the other hand these values in the non-infected control were  $45.220 \pm 7.2834$ ,  $8.644 \pm 0.7118$  and  $5.542 \pm 1.1305$  with P value (= 0.684, < 0.001 and 0.001) respectively by using T-test for the statistical comparison also there was a significant difference between patients and control as regard Helicobacter antibody titer  $36.16 \pm 19.736$  and  $5.82 \pm 1.804$  P value < 0.001 Meanwhile, by using ROC curve there was insignificant difference for PGI with H pylori infection (Cut off value for PGI is 34.8 ng/ml with sensitivity of 82 % and specificity 75%) and there was high significant difference for PGII with H pylori infection (Cut off value for PGII is 8.7 ng/ml with sensitivity of 87.5 % and specificity 80%)

**Conclusion:** there was insignificant increase in PGI, high significant increase in PGII, significant decrease in PGI: PGII ratio. Statistical difference for H.pylori antibody titer in the serum levels between the estimated two groups.

**Key words:** Pepsinogen (PG) & Helicobacter pylori (HP)

### Introduction

Pepsinogen is a precursor of pepsin, and human gastric mucosa cells produce two immunologically distinct forms of PG. (Samloff IM, 2017 and Kikuchi S, Wada O, Miki K, et al., 1994) PG I is secreted by the chief and mucus neck cells in the gastric fundic glands, and PG II is produced by these cells and by the cardiac, pyloric, and Brunner's glands in the gastric cardia and antrum and proximal duodenum. (Rotter JI, Wong FL, Samloff IM, et al. 1982) PG reflects gastric mucosal atrophy and inflammation, both of which Helicobacter pylori (H. pylori) infection provokes. Inflammation upregulates production of both PG I and PG II in gastric mucosal cells and increases the amount discharged to serum, where elevation of

PG II is usually larger so that the PG I: II ratio declines. With the progression of atrophy, numbers of gastric mucosal cells producing PG II and I decrease. As the decrease of cells producing PG I is more crucial, the PG I:II ratio declines with the progression of atrophy. (Miki K, Ichinose M, Shimizu A, et al., 1987 and Inoue K, Fujisawa T, Haruma K. 2010) In adults, PG values were used as a marker of gastric mucosal atrophy that is strongly related to gastric cancer risk. (Kikuchi S, Kato M, Mabe K, et al., 2017 and Kikuchi S, Wada O, Nakajima T, et al., 1995). Recently, criteria of PG values to distinguish subjects with and without H. pylori infection have been proposed because PG values differ depending on the infection among adult subjects. (Kikuchi S,

Nakajima T, Kobayashi O, et al., 2017). adults with *H. pylori* infection showed elevated PG I and PG II values and reduced PG I to PG II ratios. (Nakayama Y, Lin Y, Hongo M, Hidaka H, Kikuchi S, 2017). *H. pylori* infection causes lesions in most infected population, including nodular atrophic gastritis and duodenal erosion: ulcer, (Fukuda Y, Isomoto H, Ohnita K, et al., 2003) and a subset of infected subjects develop gastric cancer in the future. (Sipponen P, Härkönen M, Alanko A et al., 2002 and Mardh E, Mardh S, Mardh B et al 2002) In a previous study with 45 asymptomatic subjects aged 25-50 years. (Fukuda Y, Isomoto H, Ohnita K, et al., 2003) and another study analyzing sera from 120 asymptomatic individuals less than 45 years old, serum *H. pylori* antibody-positive subjects showed elevated PG I and PG II, and reduced PG I:II compared with the seronegative people. Thus, PG values can be used to diagnose *H. pylori* infection status in these intended patients. Nonetheless, it is still unclear whether distributions of PG values is variable and affected by age differences with reference to *H. pylori* infection status. The previous studies did not focused on these points. The inflamed gastric mucosa transmits specific factors to the blood, which allows the possibility of diagnosing gastritis by serologic analysis. A number of serologic markers have been described, such as pepsinogen I (PGI), pepsinogen II (PGII) and IgG antibodies against *Helicobacter pylori*. (Okuda M, Kamiya S, Booka M, et al., 2013).

Many studies have been done in Europe and Japan, (Mabe K, Kikuchi S, Okuda M, et al., 2017 and Kikuchi S. 2015 ) but because of potential ethnic, dietary, environmental and disease differences, the use of serum pepsinogen (PG) screening requires local validation. (Ueda J, Okuda M, Nishiyama T, et al., 2014).

There are no data available in Egypt on the serologic PG concentrations in patients with (HP), so we decided to use serum PG as the biomarker in the development of a novel noninvasive test, as the first option for a screening test for (HP) diagnosis & prevalence in Egyptian patients. The aim of this study was to assess the distributions of PG values in *H. pylori* infected and non-infected subjects in adult Egyptian population.

Subjects and methods:

The sample collection was conducted in Sayed Galal Hospital, Al-Azhar University. They were healthy subjects aged 25 –50 years and were asked to serum samples. The participants were informed of the study and gave the written consent. Blood samples were assayed using *H. pylori* IgG antibody kits. In addition, PG I and PG II levels were measured in the serum samples. For the serum antibody tests, serum *H. pylori* IgG antibody was quantified using a serum-HpELISA kit (E-plate EIKEN *H. pylori*, Eiken Chemical Co., Ltd. Japan). According to the manufacturer's instruction, serum antibody titers  $\geq 10.0\text{U/mL}$  and titers  $< 10.0\text{U/mL}$  were classified as positive and negative for *H. pylori*, respectively. The cutoff value gave 91.2% sensitivity and 97.4% specificity for adult subjects... (Kalach N, Legoedec J, Wann AR, Bergeret M, Dupont C, Raymond J. 2004) Levels of PG I and PG II and the ratio of PG I to PG II were evaluated between positive and negative (control) serum antibody tests.

Statistical analyses:

Data were analyzed using Statistical Program for Social Science version 18.0. Quantitative data were expressed as mean  $\pm$  standard deviation. Qualitative data were expressed as frequency and percentage. The comparison between two assessed groups were statistically analyzed by T. test

Probability (P-value)

P-value  $< 0.05$  was considered significant. (Sig).

P-value  $< 0.01$  was considered as highly significant.

P-value  $> 0.05$  was considered non significant

Receiver operating characteristic (ROC) curves were used to evaluate the PGI, PGII serum levels for *H. pylori* infection with area under the curve was 0.437 and 0.816 with P value = 0.281 &  $< 0.001$  respectively

## Results


In this study, 100 subjects were participated, of all blood sample provided, comparison between mean serum level between control and *H. pylori* infected patients, (Figure 1). Also the comparison between two groups as regard serum levels for PGI, PGII, antibody *H. pylori* titer and for Age using T. test & P value (Table 1). For control Ab *H. pylori* titer for control considered if below 10U/ml but for infected patients above 10U/ml. there was non-significant increase for PGI P value=0.684 but for PGII PGI:PGII and in *H. pylori* Ab titer show significant increase P

value <0.001 also there was increase in the mean serum levels in infected patients if compared with normal control (Figure 2). In the other hand and by using ROC curve there was non- significant statistical difference in PGI for H. pylori infection with Cut off value for PGI is 34.8ng/ml with sensitivity of 82% and specificity 75% P value=0.281 (Figure 3) meanwhile for PGII Cut off value is 8.7ng/ml with sensitivity of 87.5% and specificity 80% P value<0.001 (Figure 4). The serum levels for PG I and PG II values and PG I to PG II ratio (PG I:II) were assessed, whereas in the infected subjects, these values were 46.618 ± 19.5031, 15.700± 8.2721 and 3.166±0.5528 respectively in the other hand these values in the non-


infected control were 45.220 ± 7.2834, 8.644 ± 0.7118 and 5.542±1.1305 with P value (=0.684, <0.001 and 0.001) respectively by using T-test for the statistical comparison (Table 1), also there was a significant difference between patients and control as regard helicobacter antibody titer 36.16±19.736 and 5.82±1.804 P value < 0.001 .also by using ROC curve there was insignificant difference for PGI with H pylori infection (Cut off value for PGI is 34.8 ng/ml with sensitivity of 82% and specificity 75%) and there was high significant difference for PGII with H pylori infection (Cut off value for PGII is 8.7 ng/ml with sensitivity of 87.5% and specificity 80%.

**Table (1):** Comparison between Control and Patients in Age, PGI, PGII, and Serum Ab titer foe HP Helicobacter by using (T- test).There is statistically significant difference between two groups in PGI, PGII and Serum Ab titer for HP


	Group No/50 for each	Mean	SD	P Value
Pepsinogen I(PGI) ng/ml	Control	45.220	7.2834	0.684
	Patients	46.618	19.5031	
Pepsinogen II(PGI) ng/ml	Control	8.644	.7118	<b>0.001</b>
	Patients	15.700	8.2721	
PGI/PGII Ratio	Control	5.542	1.1305	<b>0.001</b>
	Patients	3.166	.5528	
Age /years	Control	45.40	9.920	0.725
	Patients	46.06	8.765	
Serum Ab titer for HP	Control	5.82	1.804	<b>0.001</b>
	Patients	36.16	19.736	



**Figure (1):** Comparison between mean of serum levels in Control and Patients: PGI, PGII, PGI/PGII ratio



**Figure (2):** Mean Serum AB titer/U for HP between control and patients.




**Figure (3):** ROC curve of Serum PGI for H. Pylori infection.

**Table (2):** ROC curve of Serum PGI for H. Pylori infection.

Cut off value for PGI is 34.8 ng/ml with sensitivity of 82 % and specificity 75%

	Area under the curve	S. Error	95% CI	P value
<b>Pepsinogen I(PGI) ng/ml</b>	0.437	0.061	0.318-0.557	0.281



Diagonal segments are produced by ties.

**Figure (4):** ROC curve of Serum PGII for H. Pylori infection.

**Table (3):** ROC curve of Serum PGII for H. Pylori infection.

Cut off value for PGII is 8.7 ng/ml with sensitivity of 87.5 % and specificity 80%

	Area under the curve	S. Error	95% CI	P value
<b>Pepsinogen II(PGII) ng/ml</b>	0.816	0.049	0.720-0.912	<b>0.001</b>

**Discussion**

50 out of 100 subjects gave positive results for serum antibody titer considered H. pylori infected > 10U/ml, and 50 control group with negative serum antibody titers of <10U/mL were considered no infected. In the H. pylori non-infected subjects, the means of PG I, PG II, and the PG I:II ratio were 45.22 ng/ml, 8.644 ng/ml, and 5.542 respectively, whereas in the infected subjects, these values were 46.618ng/mL, 15.700ng/mL, and 3.166, respectively (each P=0.684 and P <0.001; respectively (Table 1). In the previous studies with asymptomatic Japanese people the elevated PG I and PG II levels and the decreased PG I:II ratio in H. pylori infected subjects were consistent with the present study except for PGI serum level not significantly

increased. In asymptomatic people aged 40-50 years in Chile, similar results were obtained, while the PG I:II ratio was elevated in the H. pylori seropositive population. (Koilvusalo AI, Pakarinen MP, Kolho KL 2007). In symptomatic patients, PG I and II were elevated and the PG I:II ratio was decreased in H. pylori seropositive patients, (de Angelis GL, Cavallaro LG, Maffini V, et al., 2007 and Kitamura Y, Yoshihara M, Ito M, et al., 2015) although a few exceptional results were reported, where PG I was not affected coinciding with our study or the PG I: II ratio was not affected. The elevated PG I and PG II and decreased PG I: II ratio in H. pylori infected patients seem to be consistent, although several exceptions exist. The change in PG values in the infected children were

similar to those of adult subjects without severe mucosal atrophy (Inoue K, Fujisawa T, Haruma K. 2010). PG I and PG II values can be affected by the kits that are used and the different criteria are proposed. (Kikuchi S, Nakajima T, Kobayashi O, et al., 2000 and Khanna B, Cutler A, Israel NR, et al., 1998) One study that used the same kit as the present study reported a 96.3% sensitivity and 82.8% specificity in adult subjects when a PG II value of  $\geq 28$  ng/mL or a PG I:II ratio of  $\leq 8.0$  were considered positive for the diagnosis of *H. pylori* infection. (Kikuchi S, Nakajima T, Kobayashi O, et al 2017). Nonetheless, 100% sensitivity and 81.9% specificity are obtained when PG II values of  $\geq 31$  ng/mL or PG I: II ratios of  $\leq 5.3$  are used to determine *H. pylori* infection status. ROC of PG II indicates 8.7 ng/ml with sensitivity of 87.5% and specificity 80% was the cutoff value available in this work. *H. pylori* infection in Egyptian sampled population and can be used with a serum antibody test as another marker of the infection to improve the diagnostic accuracy. The limitations in the present study were, First, the sample size of *H. pylori* positive subjects was relatively small and the small sample size might make the results unstable. The results of the present study regarding *H. pylori* positive subjects were consistent with other studies. (So JB-Y, Yeoh K-G, Mochala S et al. 2002 and Zagari RM, Nicolini G, Casanova S et al., 2002).

The effect of *H. pylori* infection on PG values may be typical, and the small sample size may not have a large effect... Some reports have suggested that the antibody test is inaccurate for the diagnosis of *H. pylori* infection in children, (Sunnerstam B, Kjerstadius T, Jansson L, et al., 1999) but the both serum and urine antibody kits showed a good diagnostic accuracy. (Koivusalo AI, Pakarinen MP, Kolho KL 2007 and Lopes AI, Palha A, Lopes T, et al., 2006, and Okuda M, Osaki T, Lin Y, et al., 2015)

So, we recommend urine and serum samples to be assessed in future studies. We excluded 4 subjects with discrepant results and 2 subjects with negative high titers of serum antibody.

In conclusion, PG I values not affected and PG II values were higher and the PG I: II ratio was

lower in *H. pylori* infected adult Egyptian patients compared to non-infected people. Therefore, PG serum levels considered significant markers to differentiate *Pylori* infected from healthy Egyptian individuals.

## References

1. Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. *Gastroenterology*. 1971;61:185–188.
2. Rotter JI, Wong FL, Samloff IM, et al., Evidence for a major dominance component in the variation of serum pepsinogen I levels. *Am J Hum Genet*. 1982;34:395–401.
3. Miki K, Ichinose M, Shimizu A, et al., Serum pepsinogens as a screening test of extensive chronic gastritis. *Gastroenterol Jpn*. 1987; 22:133–141.
4. Inoue K, Fujisawa T, Haruma K. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum *Helicobacter pylori* antibodies. *Int J Biol Markers*. 2010; 25:207–212.
5. Kikuchi S, Wada O, Miki K, et al. Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. *Cancer*. 1994; 73:2695–2702.
6. Miki K, Ichinose M, Ishikawa KB, et al., Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. *Jpn J Cancer Res*. 1993; 84: 1086–1090.
7. Kikuchi S, Kato M, Mabe K, et al., Optimal criteria and diagnostic ability of serum PG values for *Helicobacter pylori* infection. *J Epidemiol*. doi:10.2188= jea. JE20170094
8. Kikuchi S, Kato M, Mabe K, et al., Introduction of an examination and treatment for *Helicobacter pylori* infection in high school health screening. *J Gastroenterol*. 2011;46:1353–1360.
9. Kikuchi S, Wada O, Nakajima T, et al., Prevention of gastric carcinoma among young adults: serum anti-*Helicobacter pylori* antibody and gastric cancer among young adults. *Cancer*. 1995;75:2789–2793.
10. Kikuchi S, Nakajima T, Kobayashi O, et al., Effect of age on the relationship

- between gastric cancer and *Helicobacter pylori*. *Jpn J Cancer Res.* 2017; 91:774–779.
11. Nakayama Y, Lin Y, Hongo M, Hidaka H, Kikuchi S. *Helicobacter pylori* infection and its related factors in junior high school students in Nagano Prefecture, Japan. *Helicobacter.* 2017; 22:e12363.
  12. Fukuda Y, Isomoto H, Ohnita K, et al., Impact of CagA status on serum gastrin and pepsinogen I and II concentrations in Japanese children with *Helicobacter pylori* Infection. *J Int Med Res.* 2003; 31: 247–252.
  13. Sipponen P, Härkönen M, Alanko A et al., Diagnosis of atrophic gastritis from a serum sample. *Clin Lab* 2002; 48:505–15.
  14. Mardh E, Mardh S, Mardh B et al. Diagnosis of gastritis by means of a combination of serological analyses. *Clin Chim Acta* 2002; 320: 17–27.
  15. So JB-Y, Yeoh K-G, Mochala S et al., Serum pepsinogen levels in gastric cancer patients and their relationship with *Helicobacter pylori* infection: a prospective study. *Gastric Cancer* 2002;5: 228–32.
  16. Zagari RM, Nicolini G, Casanova S et al., Diagnosis of atrophic gastritis in the general population based upon a combination of three non-invasive tests. *Gut* 2002; 51(Suppl 11): A39.
  17. Okuda M, Kamiya S, Booka M, et al., Diagnostic accuracy of urine-based kits for detection of *Helicobacter pylori* antibody in children. *Pediatr Int.* 2013;55: 337–341.
  18. Mabe K, Kikuchi S, Okuda M, et al., Diagnostic accuracy of urine *Helicobacter pylori* antibody test in junior and senior high school students in Japan. *Helicobacter.* 2017 Jul 11. doi:10.1111=hel.12329
  19. Ueda J, Okuda M, Nishiyama T, et al., Diagnostic accuracy of serum antibody kit (E-plate) in the detection of *Helicobacter pylori* infection in Japanese children. *J Epidemiol.* 2014;24:47–51.
  20. Kikuchi S. Background of and process to “Warning from Japanese Society for *Helicobacter* Research on positive or negative decision by serum *Helicobacter pylori* IgG antibody tests (Dec. the 25th, 2014)”. *Jpn J Helico Res.* 2015; 17:21–24 (in Japanese).
  21. Muhsen K, Lagos R, Reymann MK, Graham DY, Pasetti MF, Levine MM. Age-dependent association among *Helicobacter pylori* infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgR. *PLoS One.* 2014; 9(1): e83999.
  22. Guariso G, Basso D, Bortoluzzi CF, et al., Gastro Panel: evaluation of the usefulness in the diagnosis of gastro-duodenal mucosal alterations in children. *Clin Chim Acta.* 2009; 402:54–60.
  23. Kalach N, Legoedec J, Wann AR, Bergeret M, Dupont C, Raymond J. Serum levels of pepsinogen I, pepsinogen II, and gastrin-17 in the course of *Helicobacter pylori* gastritis in pediatrics (Letter to Editor). *J Pediatr Gastroenterol Nutr.* 2004; 39:568–569.
  24. de Angelis GL, Cavallaro LG, Maffini V, et al., Usefulness of a serological panel test in the assessment of gastritis in symptomatic children. *Dig Dis.* 2007;25:206–213.
  25. Koilvusalo AI, Pakarinen MP, Kolho KL. Is GastroPanel serum assay useful in the diagnosis of *Helicobacter pylori* infection and associated gastritis in children? *Diagn Microbiol Infect Dis.* 2007; 57:35–38.
  26. Lopes AI, Palha A, Lopes T, et al., Relationship among serum pepsinogens, serum gastrin, gastric mucosal histology and H-*pylori* virulence factors in a paediatric population. *Scand J Gastroenterol.* 2006; 41:524–531.
  27. Kitamura Y, Yoshihara M, Ito M, et al., Diagnosis of *Helicobacter pylori*-induced gastritis by serum pepsinogen levels. *J Gastroenterol Hepatol.* 2015;30:1473–1477.
  28. Okuda M, Osaki T, Lin Y, et al., Low prevalence and incidence of *Helicobacter pylori* infection in children: a population-based study in Japan. *Helicobacter.* 2015;20:133–138.
  29. Khanna B, Cutler A, Israel NR, et al., Use caution with serologic testing for *Helicobacter pylori* infection in children. *J Infect Dis.* 1998;178:460–465.

30. Sunnerstam B, Kjerstadius T, Jansson L, et al., Detection of Helicobacter pylori antibodies in a pediatric patient popu-

lation: comparison of three commercially available serological tests and one in-house enzyme immunoassay. J Clin Microbiol. 1999; 37: 28–33.

### الملخص العربي

الدور التشخيصي لقياس مستوى الببسونجين في دم المرضى المصابين بالجرثومة الحلزونية

سيد عبد المعطي محمود محمد \* – مها عيد علي عمران \*\* - عبد الحليم حسبو \*\*\*  
 \* قسم الكيمياء الحيوية الطبية-كلية الطب بالقاهرة (بنين) – جامعة الأزهر  
 \*\* قسم الميكروبيولوجي والمناعة-كلية الصيدلة بالقاهرة (بنات)-جامعة الأزهر  
 \*\*\*قسم الباطنة -كلية الطب بالقاهرة (بنين) -جامعة الأزهر

**خلفية البحث:** بقياس مستويات الببسونجين في دم 100 من المصريين البالغين في المستوى العمري 25-50 عاما نصف هذا العدد اعتبر كمجموعة ضابطة والنصف الاخر من المرضى المصابين بالجرثومة الحلزونية حيث ان مستوى افراز الببسونجين يعكس صحة جدار المعدة وعندما تلتهب تحت تأثير الإصابة يتم افراز الببسونجين 1 وببسونجين 2 بكميات كبيرة مع زيادة نسبية للببسونجين 2 مما يسبب نقص معدل ناتج قسمتهما.

**الغرض من البحث:** تقييم مستوى الببسونجين في الدم كدلالة تشخيصية للإصابة بالجرثومة الحلزونية.  
**الطرق المستخدمة في البحث:** قد تم سحب عينات الدم من 100 شخص مصري منهم 50 كمجموعة ضابطة من الأصحاء والنصف الأخر كمجموعة من المرضى المصابين بالجرثومة الحلزونية وقد تم قياس مستوى الببسونجين ELISA وكذلك قياس معدلات مضادات الجرثومة. وقد تم تقدير الدلالة الإحصائية عن طريق (ROC curve و T-test).  
**نتائج البحث:** لوحظ أنه ليس هناك فروق ذات دلالة إحصائية بين المجموعتين الضابطة والمریضة بخصوص مستوى ببسونجين 1 وهناك زيادة ذات دلالة إحصائية في مستوى ببسونجين 2 وكذلك نقص ذو دلالة إحصائية في معدل ببسونجين 1: ببسونجين 2 وعلي الجانب الآخر هناك زيادة في معدل قياس مضادات الجرثومة في دم المرضى بالمقارنة بالمجموعة الضابطة.  
**الخلاصة:** يمكن اعتبار قياس مستوى ببسونجين 1 وببسونجين 2 ومعدل ببسونجين 1: ببسونجين 2 له دلالة احصائية في تشخيص المرضى المصريين المصابين بالجرثومة الحلزونية.